ImmunityBio Inc is a biotechnology company focused on developing innovative immunotherapy treatments to harness the body's immune system in the fight against cancer and infectious diseases. The company specializes in the discovery and commercialization of novel therapies that aim to stimulate an immune response, with a particular emphasis on enhancing the effectiveness of existing cancer treatments. By leveraging cutting-edge research and technology, ImmunityBio is dedicated to improving patient outcomes and finding breakthrough solutions for complex medical challenges. Read More
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ImmunityBio (IBRX) To Contact Him Directly To Discuss Their Options
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors concerning the Company’s possible violations of federal securities laws.
The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2025, both dates inclusive (the “Class Period”), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v. ImmunityBio, Inc., No. 26-cv-03261 (C.D. Cal.), the ImmunityBio class action lawsuit charges ImmunityBio and ImmunityBio’s Executive Chairman with violations of the Securities Exchange Act of 1934.
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities during the period of January 19, 2026 through March 24, 2026, inclusive (“the Class Period”).
The Law Offices of Frank R. Cruz announces an investigation of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for ImmunityBio investors under the federal securities laws.
A diverse group of small- and mid-cap companies across defense technology, digital assets, biotech, energy, and education are drawing increased investor focus as new developments signal potential momentum heading into the next market cycle. From U.S. Marine Corps VR deployments to $1B debt reduction moves and biotech trial validation, multiple sectors are driving renewed investor attention.
NEW YORK, NY - March 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).
ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based on the Independent Data Monitoring Committee (IDMC) review of the interim data, the committee recommended that the study is adequately powered to detect the pre-specified clinically meaningful difference in complete response (CR) rate between the experimental arm (ANKTIVA + BCG) and the control arm (BCG alone) at the protocol-specified power, in the randomized QUILT-2.005 (NCT02138734) study. The QUILT-2.005 study was designed to detect the pre-specified difference in CR rate between ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) and BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary disease, based on its review of the planned interim analysis.
NEW YORK, NY - March 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) resulting from allegations that ImmunityBio, Inc. may have issued materially misleading business information to the investing public.
ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China has granted regulatory approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln).
